Key Highlights

  • Consensus EPS of 1.19 compares with second-quarter diluted EPS of 0.76, against a loss of 4.00 last year.
  • Consensus revenue of USD 238.00 million compares with net sales of USD 216.8 million, up 6.9% from the prior year.
  • Gross margin was 32.5% against 31.6% a year earlier, and the company reported an operating margin of 9.2%.
  • Net sales rose USD 14.0 million, including USD 8.7 million from demand and USD 5.3 million from currency.

Rogers (NYSE:ROG) reports third-quarter results on Tuesday, Oct. 27, after the market closes. Consensus stands at EPS of 1.19 on revenue of USD 238.00 million, and the company has a market capitalization of USD 2.28 billion.

Rogers is an engineered materials company serving electronics and communications, industrial, automotive, and aerospace and defense markets. In the second quarter, it reported net sales of USD 216.8 million against USD 202.8 million and gross profit of USD 70.4 million against USD 64.0 million.

Estimates Against the Last Reported Quarter

The EPS estimate of 1.19 is above the diluted EPS of 0.76 reported for the second quarter, which compared with a loss of 4.00 a year earlier. The revenue estimate of USD 238.00 million is above the USD 216.8 million of net sales reported.

Operating income was USD 20.0 million against an operating loss of USD 67.5 million, and income before income taxes was USD 21.4 million against a loss of USD 69.3 million. Net income was USD 13.6 million against a net loss of USD 73.6 million.

Sales, Mix and Margin Drivers

Net sales rose approximately 6.9%, or USD 14.0 million, of which USD 8.7 million came from higher demand and USD 5.3 million from currency. By end market, sales rose in electronics and communications, industrial and automotive, partly offset by lower sales in aerospace and defense.

Gross margin rose approximately 90 basis points to 32.5% from 31.6%. The filing ties the increase to higher sales volume, favorable mix and operational efficiencies, partly offset by increased raw material costs.

The company reported an operating margin of 9.2% against an operating loss of 33.3% a year earlier.

Tax Rate and Cost Detail

Cost of goods sold was USD 146.4 million against USD 138.8 million. Selling, general and administrative expenses were USD 42.2 million against USD 48.5 million, and research and development expenses were USD 7.3 million against USD 7.0 million. Restructuring and impairment charges were USD 0.7 million against USD 76.1 million. Net interest income was USD 0.3 million against USD 0.4 million.

The filing says the effective tax rate was unfavorably affected by an increase in the valuation allowance attributable to loss jurisdictions in which no tax benefit is anticipated. Its six-month tax discussion refers to a goodwill impairment in curamik for which no tax benefit is available, and the six-month tax rate was 44.6%.

The estimates table lists a market capitalization of USD 2.28 billion.

At June 30, 2026, cash and cash equivalents were USD 181.4 million against USD 197.0 million at the prior year-end, short-term investments were USD 30.0 million, and total assets were USD 1,446.4 million against USD 1,429.9 million.

Markers for the Release

Diluted EPS against 1.19 and revenue against USD 238.00 million are the headline comparisons. Other markers are gross margin against 32.5%, operating margin against 9.2% and end market sales trends.